600211 Tibet Rhodiola Pharmaceutical Holding
- 38.61
- +0.45+1.18%
Tibet Rhodiola Pharmaceutical Holding News
tibet rhodiola pharmaceutical holding (600211.SH): is currently participating in the application for the continuation of the fourth to fifth batch of national centralized drug procurement agreement expiration varieties by jiangsu alliance.
Gelonghui November 4th, Tibet Rhodiola Pharmaceutical Holding (600211.SH) stated at the performance briefing that the company is currently participating in the application work for the continued procurement of the 4th-5th batch of nationally organized pharmaceutical centralized procurement agreement-expired varieties by the jiangsu alliance. Please pay attention to the official website of the Jiangsu Provincial Medical Security Bureau for specific results.
Tibet Nordicang Pharmaceutical Co., Ltd. Report for the third quarter of 2024
tibet rhodiola pharmaceutical holding (600211.SH) released its performance for the first three quarters, with a net income of 0.792 billion yuan, a 7.42% year-on-year decrease.
tibet rhodiola pharmaceutical holding (600211.SH) released the third quarter report for 2024, with revenue for the first three quarters reaching...
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The net income for the first three quarters was 0.792 billion yuan, a year-on-year decrease of 7.42%.
On October 29th, Gelonhui reported the third quarter of 2024 of Tibet Rhodiola Pharmaceutical Holding (600211.SH). The company's revenue for the first three quarters was 2.175 billion yuan, a decrease of 8.13% year-on-year; the net income attributable to the shareholders of the listed company was 0.792 billion yuan, a decrease of 7.42% year-on-year; and the basic earnings per share was 2.46 yuan.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): Currently, there is no application for a loan to repurchase stocks plan.
Galaxy Today | Tibet Rhodiola Pharmaceutical Holding (600211.SH) stated on the investor interaction platform that the company currently has no plans to apply for loans to buy back stocks. In the future, the company will carefully consider in combination with market conditions and the actual situation of the company, and actively make decisions that are beneficial to the company's development.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): Yimdoo (China market) has obtained a supplementary application approval for pharmaceuticals.
On October 14, Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced that its wholly-owned subsidiary Tibet Nordicon Technology Development Co., Ltd. recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The drug's multifunctional treatment includes: long-term treatment of coronary heart disease, prevention of vasospastic and mixed angina, as well as long-term treatment of chronic heart failure after myocardial infarction. In 2023, the sales volume of Emuduo was 9.4906 million boxes (equivalent to 60mg), with revenue of 0.13 billion yuan, accounting for 4% of our company's main business income in 2023.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced a semi-annual equity distribution for the year 2024: a dividend of 0.967 yuan per share. The record date for the equity is August 28th.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) released its 2024 interim equity distribution implementation announcement, and this profit distribution is based on ...
Tibet Rhodiola Pharmaceutical Holding Semi-annual Report for 2023
Summary of Tibet Rhodiola Pharmaceutical Holding's H1 2024 report.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): Net income in the first half of the year was 623 million yuan, a year-on-year increase of 4.57%. The plan is to distribute dividends of 9.67 yuan per share.
On August 13th, GeLongHui reported on Tibet Rhodiola Pharmaceutical Holding(600211.SH)'s half-year report for 2024. The report period realized revenue of 1.615 billion yuan, a year-on-year decrease of 11.29%, and a net profit attributable to shareholders of listed companies of 0.623 billion yuan, a year-on-year increase of 4.57%. Excluding non-recurring gains and losses, the net profit attributable to shareholders of listed companies was 0.524 billion yuan, a year-on-year decrease of 9.85%. Basic earnings per share were 1.93 yuan. Based on the company's current operational situation, the company plans to distribute profits based on the total share capital that participants can receive on the date of registration of equity distribution plan. Board of directors will distribute 1.05 yuan cash dividend per share to all shareholders for every 10 shares held
Tibet Rhodiola Pharmaceutical Holding (600211.SH): There is currently no specific plan for overseas sales of their main product, Xinhuosu.
On July 11th, Gloden Investment Network received inquiries from an investor on the investor Q&A platform regarding Tibet Rhodiola Pharmaceutical Holding (600211.SH), asking: "Does the company's main product have the potential and plan to expand overseas? Are there products with similar efficacy overseas?" The company replied that the main product, Xinhuosu, does not currently have a specific plan for overseas sales, but the product Imdur is sold overseas. Public information shows that Xinhuosu and Nesiritide from abroad are both products used for the treatment of acute decompensated heart failure.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The new production line for Xin Huosu is expected to commence formal production in the second half of the year after registration approval.
According to the investor relations activity records disclosed by Tibet Rhodiola Pharmaceutical Holding (600211.SH) on July 10th, the new production line of Xinhuosu is expected to be put into formal production after registering and approving in the second half of the year, and the total production capacity will reach 15 million units per year. The total investment of the production line is about 0.14 billion yuan. The company is expected to complete the transfer and consolidation next year according to the accounting standards and actual situations, and then depreciate or amortize it for 12 years, which will not have a significant impact on the company's profits.
Tibet Pharmaceutical (600211.SH): The product does not cover the category of synthetic organisms
Gelonghui, May 10 丨 Tibet Pharmaceutical (600211.SH) said on the investor interactive platform that the company's products do not yet cover the category of synthetic organisms.
Tibet Pharmaceutical (600211.SH) announced first-quarter results, net profit of 313 million yuan, up 3.21% year on year
Tibet Pharmaceutical (600211.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 7.0 during the reporting period...
Tibet Pharmaceutical (600211.SH) plans to distribute 0.737 yuan per share to increase 0.3 shares in 2023, excluding interest on April 30
Tibet Pharmaceutical (600211.SH) announced that the company plans to distribute a cash dividend of 0.737 per share in 2023...
Tibet Pharmaceutical (600211.SH): Since Neoactive entered the medical insurance list in 2017, sales have risen sharply in recent years
Gelonghui, April 10 | Tibet Pharmaceutical (600211.SH) said at the performance briefing that sales of Neoactive have risen sharply in recent years since entering the medical insurance catalogue in 2017. According to the company's 2024 performance guidelines, sales of Neoactive are expected to maintain a continuous growth trend. The company will make every effort to do a good job in product sales and promote the steady growth of business performance.
Tibet Pharmaceutical (600211.SH): Received 86.2 million yuan in industrial support funds
Gelonghui, March 29丨Tibet Pharmaceutical (600211.SH) announced that the company and its subsidiary, Tibet Nordicom Pharmaceutical Co., Ltd. received 86,202,742 yuan in industrial development support funds from the Shannan Happy Home Construction Administration on March 29, 2024, accounting for 10.76% of the company's most recent (2023) audited net profit attributable to shareholders of listed companies.
Tibet Pharmaceutical (600211.SH) reported 2023 results, net profit of 801 million yuan, an increase of 116.56% year-on-year
According to the Zhitong Finance App, Tibet Pharmaceutical (600211.SH) released its 2023 annual report, achieving operating revenue of 3.134 billion yuan, an increase of 22.69% over the previous year. Achieved net profit of 801 million yuan attributable to shareholders of listed companies, an increase of 116.56% over the previous year. Achieved net profit of 784 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 112.49% over the previous year. Cash of 7.37 yuan (tax included) is distributed to all shareholders for every 10 shares, while 3 shares are added for every 10 shares using the capital reserve fund. During the reporting period, operating income increased by 22.69%, returning net profit to mother
Tibet Pharmaceutical (600211.SH): Nordicom is now gradually showing a better market pattern
Gelonghui, March 11 | Tibet Pharmaceutical (600211.SH) disclosed a record sheet of investor relations activities, showing that the company made market strategy adjustments to Nordicom products in the early stages, and the base for the previous period was low; at the same time, Nordicom is now gradually showing a better market pattern.
Tibet Pharmaceutical (600211.SH): The estimated sales volume of neovactin in 2024 is being calculated based on market demand
Gelonghui March 11 丨 Tibet Pharmaceutical (600211.SH) disclosed an investor relations activity record table showing that judging from the previous sales situation, it is normal for sales to fluctuate monthly and quarterly. Judging from the sales situation throughout the year, the development trend of neovactin will be more accurate. The specific sales data for the previous two months is still being counted. The company is counting the estimated sales volume of neovactin in 2024 based on market demand.
No Data
